Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324797 | 1.00 | FFAR1 (0.36) | FFAR1TRPV1TRPM8HTR2CHTR2B | |
| SCHEMBL3325405 | 0.84 | PNMT (0.38) | FFAR1TRPV1HTR2CHTR2BKDM4E | |
| SCHEMBL3325412 | 0.84 | PNMT (0.38) | FFAR1TRPV1HTR2CHTR2BKDM4E | |
| SCHEMBL3323275 | 0.81 | TRPV1 (0.37) | FFAR1TRPV1TRPM8 | |
| SCHEMBL3323280 | 0.81 | TRPV1 (0.37) | FFAR1TRPV1TRPM8 | |
| SCHEMBL1508366 | 0.70 | FFAR1 (0.41) | FFAR1TRPV1HTR2CHTR2BTDP1 | |
| SCHEMBL1508231 | 0.70 | FFAR1 (0.41) | FFAR1TRPV1HTR2CHTR2BTDP1 | |
| SCHEMBL3322165 | 0.69 | TRPV1 (0.44) | TRPV1TRPM8 | |
| SCHEMBL3324035 | 0.69 | TRPV1 (0.44) | TRPV1TRPM8 | |
| SCHEMBL2320590 | 0.69 | CNR1 (0.40) | TRPM8TDP1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| CN-102245587-A | Trpv1 antagonists | ABBOTT LAB | 2011-11-16 | — | — | CN | disclosed |
| CN-102186836-A | Trpv1 antagonists | ABBOTT LAB | 2011-09-14 | — | — | CN | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | FFAR1 125/4885TRPV1 1/4885TRPM8 8/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | FFAR1 120/4885TRPV1 1/4885TRPM8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.